← All trials
NCT00637728
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2006
- Primary completion
- Sep 1, 2006
- Completion date
- Sep 1, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- 5
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Par PharmaceuticalsLead sponsor
- Western Maryland Health SystemOverall official - principal investigator
- Innovative Medical Research of South Florida, IncOverall official - principal investigator
- Par PharmaceuticalsStudy chair
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.